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Supplementary Material 
 
Supplementary Methods 
 
Cell cycle experiments 
Asynchronous A549 cells were transfected with siRNAs and 72hr later were fixed in ethanol 
prior to propidium iodide staining to determine DNA content.  The fluorescence of single cells 
was quantified by flow cytometry using a BD FACScaliburTM system and WinMDI software.  
For mitotic counts, asynchronous A549 cells were seeded onto coverslips, transfected with 
siRNAs for 72hr, then stained for tubulin and DAP1. The percentage of cells in mitosis was 
scored using a Nikon Eclipse Ti (CFI Plan Apochromat 40× N.A. 0.95, W.D. 0.14mm) 
microscope. 
 
Ub-VME binding assays 
Cells were lysed in non-denaturing buffer (50mM Tris pH: 7.5, 5mM MgCl2, 250mM 
sucrose,1mM DTT, 2mM ATP) on ice and homogenized by progressively passing through 
23G, 26G and 30G needles with PhosStop (Roche) added immediately.  Lysates were cleared 
by centrifugation (20min, 14,000rpm, 4°C), a BCA assay performed and protein 
concentrations standardized to 0.5mg/ml. 15μg protein was incubated with 75ng Ha-Ub-VME 
(UbiQ) for at 37°C with shaking at 300rpm. 5x sample buffer (15% SDS, 50% Glycerol, 16% 
2-Mercaptoethanol, 0.5% Bromophenol Blue, 312.5mM Tris pH 6.8) was added and samples 
heated at 95°C for 5min to terminate the reaction before analysis by immunoblotting. 
 
Immunoprecipitation of GFP-USP15 constructs from synchronized cells for mass 
spectrometry  
A549 cells were transfected with GFP-USP15 plasmids and synchronized at G1/S or G2/M, 
as described in main materials and methods. Cells were lysed in NP-40 buffer (25mM Tris pH 
7.5, 100mM NaCl, 50mM NaF, 0.5 % (w/v) NP-40, 2mM MgCl2, 1mM EGTA, Complete 
Mammalian Proteases Inhibitors (Roche) and PhosStop (Roche)) with rocking on ice for 
15min.  The protein concentration of each sample was determined after suitable dilution using 
a Bicinchoninic Acid (BCA) assay (Thermo Scientific) and 2mg lysate used for each 
immunoprecipitation. An anti-GFP single chain antibody (GFP-nanotrap) was coupled to 
sepharose beads, added to lysates and incubated at 4°C overnight with rotation. Beads were 
pelleted and washed three times in Wash buffer 1 (25mM Tris pH7.5, 50mM NaCl, 50mM NaF, 
0.05% (w/v) NP-40, 2mM MgCl2 with mammalian protease inhibitors and PhosStop) then once 
in Wash buffer 2 (10mM Tris pH 7.5, 2mM MgCl2).  The beads were boiled for 5min with 
intermittent vortexing in 2% SDS to elute bound proteins. Prior to running on a gel, samples 
were reduced (boiled 2min with 10mM DTT) and alkylated (chloroacetamide added to 50mM 
for 30min, room temperature in dark). The immunoprecipitation eluate was separated on 
NuPAGE Novex 4–12% Bis-Tris Gels (Invitrogen), the band corresponding to GFP-USP15 cut 
out and processed for mass spectrometry as described in the main materials and methods, 
but omitting reduction and alkylation during the in gel-digest and using (m/z 300–2000). 
 
 
Supplementary Figure Legends 
 
Supplementary Figure S1. Expression of USP15 splice variants and isoforms in A549 
cells. 
a, Schematic of the USP15 isoforms (top), showing the 28 amino acid serine-rich cassette 
unique to isoform 1, and the alternative splice variants that encode them (below) illustrating 
the position of isoform-specific primers and siRNAs.  b & c, Independent depletion of the 
USP15 isoforms. A549 cells were transfected for 72hr with siRNAs targeting isoform-1, 
isoform-2, or both USP15 isoforms (USP15-P). (b) Total RNA was analysed by qRT-PCR for 
the two USP15 splice variants, data are normalised to actin and relative to the non-targeting 
siRNA siCON2. (c) Whole cell protein extracts were subject to immunoblotting for USP15, a 
representative experiment is shown with quantitation of the two isoforms (below). 
 
Supplementary Figure S2. USP15 depletion does not alter cell cycle distribution. 
a, Flow cytometry analysis of A549 cells 72hr post siRNA transfection.  Single cells were gated 
based on propidium iodide intensity; histogram shows the distribution of the cell population 
between cell cycle phases. b, The mitotic index was counted for A549 cells 72hr post siRNA 
transfection.  
 
Supplementary Figure S3. Mitotic S229 phosphorylation of USP15 isoform-1. 
Schematic shows the experimental strategy to identify phosphorylated residues. GFP-USP15-
iso1 or GFP-USP15-iso2 were transfected into A549 cells and protein extracts from cells 
arrested at either G1/S or G2/M were immunoprecipitated using a GFP-nanotrap. 
Immunoprecipitated proteins were compared by immunoblotting (right) or processed for mass 
spectrometry (left).  All identified USP15 peptides, and the single phosphopeptide identified at 
G2/M, are shown mapped to isoform-1. 
 
Supplementary Figure S4. USP15 S229 phospho-mutants localise similarly to 
wild-type USP15 isoform-1.  
A549 cells were transfected with the indicated GFP-USP15 constructs or GFP only as a 
control. Cells were fixed and co-stained for the cell cycle phase marker cyclin B1 and DAPI, 
to classify cells as G1 or S-phase (low cytoplasmic cyclin B1), G2 (high cytoplasmic cyclin B1) 
or prophase (nuclear cyclin B1, uncondensed chromatin). Representative 
immunofluorescence images of cells expressing the USP15 isoform-1 C298S catalytic mutant, 
or the S229 phospho-mutants in G2 cells and prophase cells; scale bars 10µm. Transfected 
cells were scored for relative intensity of GFP-USP15 variant expression in the nucleus 
compared to the cytoplasm, illustrated in Figure 7. 
 
Supplementary Figure S5. Both USP15 isoforms are catalytically reactive. 
Detergent-free extracts from A549 cells were incubated with the ubiquitin active site directed 
probe Ub-VME at a ratio of 200:1 protein:probe for the indicated time.  Analysis by 
immunoblotting shows an 8kDa gel mobility shift for reactive USP15 that has bound to Ub-
VME.  a, Endogenously expressed isoform-1 and isoform-2 are both reactive towards Ub-
VME. b, Phospho-mimetic and non-phosphorylatable forms of USP15 isoform-1 are 
catalytically reactive towards Ub-VME. A549 cells were transfected with the indicated USP15 
isoform constructs: wild-type (WT), catalytically inactive (C298S or C269S) or phospho-mutant 
forms of isoform 1 (S229A, S229D), and extracts were incubated with Ub-VME for 15min. 
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